This document discusses pharmacotherapy for diabetes mellitus. It begins by defining diabetes and describing the long-term damage it can cause. It then provides statistics on diabetes prevalence in India. The main types of diabetes - type 1, type 2, and gestational - are classified and their characteristics summarized. The mechanisms and treatments of type 1 and type 2 diabetes are explained at a high level. The document also briefly outlines diabetes investigation methods, treatment guidelines, insulin discovery and mechanisms of action, and types of insulin preparations.
A brief description of Diabetes with management guidelines
according to different diabetes foundation and their treatment with drugs and their MOA dose and side effects
This was a presentation delivered at Gandhinagar on 18th August 2017. This is a talk on a Case of Adolescent Type 2 Diabetes successfully managed with Basal Insulin with Metformin
Diabetic Dyslipidemia
By Dr. Usama Ragab Youssif
ISMA CME Activity 2021
In Tolip EL Galala Hotel
-----------
Introduction
Physiology of lipid metabolism
Pathophysiology of diabetic dyslipidemia
Statin therapy (+/- ezetimibe) evidence and translation of evidence
Residual CV risk: excess TG
EPA therapy evidence and translation of evidence
A brief description of Diabetes with management guidelines
according to different diabetes foundation and their treatment with drugs and their MOA dose and side effects
This was a presentation delivered at Gandhinagar on 18th August 2017. This is a talk on a Case of Adolescent Type 2 Diabetes successfully managed with Basal Insulin with Metformin
Diabetic Dyslipidemia
By Dr. Usama Ragab Youssif
ISMA CME Activity 2021
In Tolip EL Galala Hotel
-----------
Introduction
Physiology of lipid metabolism
Pathophysiology of diabetic dyslipidemia
Statin therapy (+/- ezetimibe) evidence and translation of evidence
Residual CV risk: excess TG
EPA therapy evidence and translation of evidence
In this presentation, all topics related to diabetes are mentioned anf if you want any topic in mre detail then please let me know. In this presentation dibetes definition, causes, types, treatment, management is mentioned.
Managment of Diabesity (Obesity in diabetes mellitus) Tarek Al 3reeny
This presentation summaries state of the art management of obesity in diabetes mellitus (diabesity) including definition and classifications of both obesity and diabetes. Multidisciplinary approach , pharmacotherapy & bariatric surgery
Insulin Types
By Dr. Usama Ragab Youssif
In light of Insulin Workshop - 3rd Annual ISMA Conference 2021
It includes Insulin history, insulin types, insulin action
In this presentation, all topics related to diabetes are mentioned anf if you want any topic in mre detail then please let me know. In this presentation dibetes definition, causes, types, treatment, management is mentioned.
Managment of Diabesity (Obesity in diabetes mellitus) Tarek Al 3reeny
This presentation summaries state of the art management of obesity in diabetes mellitus (diabesity) including definition and classifications of both obesity and diabetes. Multidisciplinary approach , pharmacotherapy & bariatric surgery
Insulin Types
By Dr. Usama Ragab Youssif
In light of Insulin Workshop - 3rd Annual ISMA Conference 2021
It includes Insulin history, insulin types, insulin action
Bioassay (commonly used shorthand for biological assay), or biological standardization is a type of scientific experiment. A bioassay involves the use of a live animal (in vivo) or tissue (in vitro) to determine the biological activity of a substance, such as a hormone or drug. Bioassays are typically conducted to measure the effects of a substance on a living organism and are essential in the development of new drugs and in monitoring environmental pollutants. Both are procedures by which the potency or the nature of a substance is estimated by studying its effects on living matter. A bioassay can also be used to determine the concentration of a particular constitution of a mixture.
Diabetes mellitus (DM) is a syndrome of chronic hyperglycaemia is due to one of two mechanisms:
Inadequate production of insulin , or
Inadequate sensitivity of cells to the action of insulin.
It affects more than 220 million people worldwide, and it is estimated that it will affect 440 million by the year 2030
"Diabetes" comes from the Greek word for "siphon", and implies that a lot of urine is made.
The second term,"mellitus" comes from the Latin word, "mel" which means "honey", and was used because the urine was sweet.
• The onset of type 1 diabetes may also be associated with sudden weight loss or nausea, vomiting, or abdominal pains, if DKA has developed.
Nursing Management · Monitor blood sugar and use a sliding scale to treat high levels of glucose · Educate patient about diabetes · Examine feet .
Diagnosis involves measuring blood glucose levels. Ongoing specialized assessment and evaluation for complications are essential for diabetes management.
Screening Models for Anti-Diabetic Drugs.Nisar Ali
in this slide, You will get to know about different screening Invivo and Invitro models used for screening of Anti-Diabetic drugs used in Pharmacology.
Diabetes mellitus, disorder of carbohydrate metabolism characterized by impaired ability of the body to produce or respond to insulin and thereby maintain proper levels of sugar (glucose) in the blood.
To know more about diabetes mellitus click on the below link
https://docmode.org/about/
https://docmode.org/lectures/
Diabetes mellitus refers to a group of diseases that affect how the body uses blood sugar (glucose). Glucose is an important source of energy for the cells that make up the muscles and tissues. It's also the brain's main source of fuel.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
2. Introduction
• Diabetes is a group of metabolic disorders
characterized by chronic hyperglycemia
associated with disturbances of carbohydrate,
fat and protein metabolism due to absolute or
relative deficiency in insulin secretion and/or
action
• Diabetes causes long term damage,
dysfunction & failure of various organs
3. Diabetes Mellitus
• "Diabetes" comes from the Greek word for
"siphon", and implies that a lot of urine is
made.
• The second term,"mellitus" comes from the
Latin word, "mel" which means "honey", and
was used because the urine was sweet.
4. Diabetes In India
• According to the Indian Council of Medical
Research-Indian Diabetes study (ICMR-
INDIAB), a national diabetes study, India
currently has 63 million people with diabetes.
• India represents the world’s second largest
diabetes population after China.
• This is set to increase to over 100 million by
2030.
• The majority of people with diabetes (>90%)
have Type 2 diabetes (T2DM).
5. Classification of Diabetes
Proposed by ADA - 1997.
• Type I:
– Absolute Insulin Deficiency due to islet cell
destruction
• Either immune mediated or idiopathic
• Type II:
– Relative insulin deficiency due to impaired -cell
function
– Marked ↑ peripheral insulin resistance
• Type III: Other Specific types
• Type IV: Gestational Diabetes
6. Type 1 DM
• Type 1 diabetes is characterized by destruction of the
pancreatic beta cells, most likely due to combined
genetic, immunologic and possibly environmental
(e.g. viral) factors which contribute to cell
destruction.
• This is abnormal response of the body in which the
antibodies are direct against the normal tissues and
eventually there is damage to Islet of Langerhans ,
specific area of the pancreas that produce insulin,
reducing the production of insulin or totally no
production of insulin.
7. Type 2 DM
• Type 2 Diabetes Mellitus is a adult onset, and
non-insulin dependent. There are 2 main
problems related to insulin in type 2 diabetes,
first one is “insulin resistance “ (insulin do not
bind with the special receptor on cell surface)
and impaired insulin secretion (insulin
secreting glands release irregular amount of
insulin).
8.
9. Differences between type-1 and type-2
Diabetes Mellitus
• Type 1
• Young age
• Normal BMI, not obese
• No immediate family history
• Short duration of symptoms
(weeks)
• Can present with diabetic
coma (diabetic ketoacidosis)
• Insulin required
• Type 2
• Middle aged, elderly
• Usually overweight/obese
• Family history usual
• Symptoms may be present
for months/years
• Do not present with
diabetic coma
• Insulin not necessarily
required
e
10. Other specific types
A) Genetic defects of Beta cell function
B) Genetic defects in Insulin action
C) Diseases of the Exocrine Pancreas
D) Secondary to Endocrinopathies
E) Drugs / Chemical induced
F) Infections
G) Uncommon form of Immune Mediated Diabetes.
H) Other Genetic Syndromes associated with Diabetes
MODY Syndromes
Lipo atrophic Diabetes
FCPD
Pancreatitis
Trauma
Neoplasia
Cystic Fibrosis
Hemochromatosis
Acromegaly
Cushings Syndrome
Pheochromocytoma
Hyperthyroidism
Steroids
Thiazides
Diazoxide
Beta Blockers
Thyroid Hormones
Congenital Rubella
CMV
Anti insulin Receptor Antibodies
Down’s Syndrome
Turners
Klinefelters
11. Gestational Diabetes
•Gestational diabetes is caused when the insulin
receptors do not function properly and glucose
intolerance increases
•This is likely due to pregnancy related factors
such as the presence of human placental lactogen
that interferes with susceptible insulin receptors.
•Increased health risk to mother and baby
•Big baby,jaundice,still birth can occur for
untreated cases
•Goes away after birth, but increased risk of
developing Type 2 DM for mother and child
15. • Polyuria - weakness
• Polydipsia - fatigue
• Polyphagia - blood sugar / glucose level
• weight loss - (+) glucose in urine (glycosuria)
nausea / vomiting
• changes in LOC
• Recurrent infection, prolonged wound healing
• Altered immune and inflammatory response, prone to
• infection (glucose inhibits the phagocytic action of WBC
• resistance)
- Genital pruritus – (hyperglycemia and glycosuria favor fungal
growth : candidal infection – resulting in pruritus, common
• presenting symptom in women)
16. INVESTIGATION
– Fasting blood sugar
– Post prandial blood sugar
– HbA1C
– Lipid Profile – To diagnose dyslipidaemia
• RBS can be done only if the patient follows up
for the diagnostic tests after a meal
17. • Person to be tested should be on a normal diet for at least 3 days prior
to testing.
•The test should be done after an overnight fast of 8 – 10 hours (no
beverages including tea or coffee should be consumed),
•Draw a sample of blood after confirming fasting state of the patient.
Fasting Serum Glucose
(mg/dl)
Diagnosis
Below 110 Normal
Between 110 and 126 Pre-diabetes
Above 126 Diabetes (Must be confirmed with a
second fasting test)
Fasting Blood Sugar
18. Post Prandial Blood Sugar
• Following the collection of the fasting blood
sample for analysis of fasting serum glucose
(FSG). Patient is advised to have a normal
meal and return to the clinic after 2 hours
following the meal.
Post prandial blood sugar Diagnosis
< 140mg/dl Normal
140-200mg/dl Pre -diabetic
>200mg/dl Diabetic
19. HbA1C
• Person to be tested should be on a normal
diet for at least 3 days prior to testing.
• The test should be done after an overnight
fast of 8 – 10 hours
HbA1C Levels Diagnosis
4 – 6 Normal for those without
diabetes
6.1-7 Target range for diabetics
>7 Poor control
20. Lipid profile
Results of lipid profile Classification
LDL
< 100 optimal
100-129 Near optimal
130-159 Borderline high
160-190 High
>190 Very high
Serum triglycerides
< 150 Optimal
150-199 Borderline high
200-499 High
>500 Very high
HDL cholesterol
< 40 Low
> 60 High
21. TREATMENT GUIDELINES
Major Risk Factors (Exclusive of LDL Cholesterol)
• Cigarette smoking
• Hypertension (BP >140/90 mmHg or on antihypertensive
medication)
• Low HDL cholesterol (<40 mg/dL)
• Family history of premature CHD
• Age (men >45 years; women >55 years)
27. Difference between human, pork, beef
insulin
Species A-chain B-chain
8th AA 10th AA 30th AA
Human THR ILEU- THR
Pork THR ILEU ALA
Beef ALA VAL ALA
28. Bioassay of insulin
• 1 IU reduces the BSL to 45 mg/dl in fasting
rabbits
• 1 mg insulin = 28 IU
• Can also be measured by radioimmunoassay
or enzyme immunoassay
29. Actions of insulin
Rapid actions Intermediary actions Long term
Sec / min Few hours > 24 hrs
E.g
Metabolic
actions
•↑ multiplication
•↑ differentiation
of cells
• Imp role in
intrauterine &
extrauterine
growth
Through DNA
e.g
• ↑ GLUT synthesis
• Synthesis of
enzymes for AA
metabolism
31. Carbohydrate metabolism
• Over all action of insulin is to ↓ glucose level
in blood
– ↑ Transport of glucose inside the cell
– ↑ Peripheral utilization of glucose
– ↑ Glycogen synthesis
– ↓ Glycogenolysis
– ↓ Gluconeogenesis
32. Lipid metabolism
• ↓ Lipolysis
• ↑ Lipogenesis
• ↑ Glycerogenesis
• ↓ Ketogenesis
• ↑ Clearance of VLDL & chylomicrons from
blood through enzyme Vascular Endothelial
Lipoprotein Lipase
33. Protein metabolism
• Facilitates AA entry and their synthesis into
proteins and inhibit breakdown in muscles
and other cellsls
Electrolyte metabolism
• ↑ transport of K+, Ca++, inorganic phosphates
34. Other actions
• Vascular actions:
– Vasodilation by Activation of endothelial NO
production
• Anti-inflammatory action
– Especially in vasculature
• Decreased fibrinolysis
• Growth
• Steroidogenesis
36. Insulin Mediated Glucose Transport
G
INS
aa
Insulin
Receptor
Complex
INS
aa
a subunit
subunit
Insulin molecule
Storage vesicle
containing
GLUT 4
Glucose
Tyrosine Kinase Activation
Metabolised Stored as Glycogen
37. Fate of insulin
• Distributed only extracellularly
• Must be given parenterally
• Addition of zinc or protein decreases its
absorption & prolongs the DOA
• Insulin released from pancreas is in
monomeric form
• Half life of insulin = 5 -9 minutes
38. Different types of insulin preparations
• Conventional preparations of insulin
– Produced from beef or pork pancreas
– 1 % of other proteins
– Potentially antigenic
• Highly purified insulin preparations
– Gel filtration reduces or ion exchange
• Human insulins
• Newer insulin analogs
40. Highly purified insulin preparations
• Single peak insulins
– Purified by gel filtration contain 50 to 200 PPM
proinsulin
– Actrapid: purified pork regular insulin
– Monotard: purified pork lente
– Mixtard: purified pork regular(30%) +
isophane(70%)
• Mono component insulins
– After gel filtration purified by ion exchange
chromatography contain 20 PPM proinsulin
– Actrapid MC, Monotard MC
41. Human insulins
• Human (Actrapid, monotard, insulatard, mixtard)
• Obtained by recombinant DNA technology
• Advantages
– More water soluble as well as hydrophobic
– More rapid SC absorption , earlier & more defined
peak
– Less allergy
• Disadvantages
– Costly
– Slightly shorter DOA
42. Indications of human insulins
• Insulin resistance
• Allergy to conventional preparations
• Injection site lipodystrophy
• During pregnancy
• Short term use of insulin
43. Newer Insulin analogs
Type Onset Peak
(Hr)
DOA
(Hr)
Rapid
acting
Lispro
Aspart
Glulisine
5-15 min
10-15 min
5-15 min
1
1
1
3-5
3-5
5-6
Long acting Glargine
Detemir
Degludec
1-2 hrs
2-3 hrs
1-2 hrs
No peak
6-8 hr
No peak
24 hr
24 hr
42 hr
44. Insulin Lispro
• Produced by Inversing proline at B28 with
lysine at B29.
• Forms weak hexamers , dissociate rapidly
• Needs to be injected immediately before or
after meals
• Better control of meal time glycemia & lower
incidence of PP hypoglycemia
45. • Insulin aspart:
– Proline at B28 replaced by aspartic acid
– Change reduces tendency for self aggregation
• Insulin glulisine
– lysine replaces aspargine at B3 & glutamic acid
replaces lysine at position B29
46. Insulin glargine
• Prepared by adding 1 glycine at A21 together with 2
arginine residues at end of B chain
• Improved Stability
• Much better bioavailabilty
• Smooth peakless effect is obtained
• Fasting & interdigestive BGL effectively lowered
irrespective of time of day
• Lower hypoglycemic episodes
• Cannot be mixed with other insulins
• Suitable for once daily injection
47. Insulin detemir
• Soluble long acting basal insulin analog with
• Flat action profile and prolonged duration
• Threonine in B30 ommited & C14 fatty acid
chain attached to amino acid B29
• Prolonged action
– Strong self association
– Albumin binding
– Fatty acid side chain
48. Insulin analogs score over
conventional insulins
• Less nocturnal hypoglycemia
• Less weight gain
• Better efficacy
• More physiological action profiles
• Less premeal lag time (0-15 mts)
• Lispro & Glulisine even after meals
• Better PP glucose control
• Improved predictability, tolerability, and flexibility
50. Uses of insulin
• Diabetes mellitus
– Must for type I diabetics
– Can be used in type II diabetics
• Diabetic ketoacidosis
• Hyperosmolar non ketotic hyperglycemic
coma
51. Indications of insulin in type II DM
• Primary or secondary failure of oral hypoglycemics
• Pregnancy
• Perioperative period
• CKD
• Steroid therapy
• LADA
• Fasting > 300 mgms HbA1c > 10
• Unintentional wt loss with or with out ketosis
• Type 2 with DKA ( severe beta cell dysfunction )
53. Insulin resistance
• State in which normal amount of insulin
produces subnormal amount of insulin
response
– ↓ insulin receptors
– ↓ affinity for receptors
• May be acute or chronic
• Requirement of > 200 Units of insulin per day
in absence of stress
• Common in type II diabetics & obese
57. PEN INJECTORS
• Easy to carry
• Easier to accurately measure dose
• more expensive than vials
JET INJECTORS
Needleless system.
Uses high pressure air to force a tiny
stream of insulin through the skin
58. Insulin Pump
Pro
• Simplified insulin
dosing
• Precise delivery
• Greater impact in those
with highest starting
A1c
• Slightly less insulin use
per day
Con
59. Inhaled Insulin (Exubera)
Advantages
Improved pt convenience
Faster onset of action compared to Regular SC insulin
No needles risk of infection
Potential earlier onset of insulin therapy in Type 2 DM
62. Mechanism of action
• Release of insulin by acting on SUR1 receptors
• Primarily augment phase 2 of insulin secretion
• Presence of at least 30% functional -cells
essential for their action.
• Minor action: ↓ glucagon secretion
• Extra pancreatic action: ↑sensitivity of
peripheral tissue to insulin by ↑insulin receptors
63.
64. Pharmacokinetics
• Well absorbed orally
• Highly bound to plasma proteins > 90%
• Have low volume of distribution
• Cross placenta C/I in pregnancy
• Metabolized in liver
• Excreted in urine
65. Daily dose & Duration of action
Sulfonylureas Doses No of
doses/day
DOA
(hrs )
1 Tolbutamide 0.5 – 2 g 2-3 6-8
2 Chlorpropramide 0.1 to 0.5 g 1 36 -48
3 Glibenclamide 5 to 15 mg 1-2 18-24
4 Gliclazide 40- 240 mg 1-2 12-24
5 Glipizide 5 to 40 mg 1-2 12-18
6 Glimepiride 1 to 6 mg 1 Upto 24
66. Individual Sulfonylurea
Sulfonylureas Special points
1 Tolbutamide Short acting, low potency , hypoglycemia
least likely
2 Chlorpropramide ↑Hypoglycemia, ↑ADH , Disulfiram Like
Reaction
3 Glibenclamide Potent but slow acting, may work when
others fail
4 Gliclazide Antiplatelet, antioxidant action, may delay
Retinopathy, less weight gain
5 Glipizide Fast acting, hypoglycemia & weight gain less
likely, prefered in elderly
6 Glimepiride More extrapancreaatic action, less
hyperinsulinemia, less hypoglycemia
67. GLIMEPIRIDE
1) Lesser risk of hypoglycemia
2) Relatively safe in elderly and mild renal failure
3) Antiplatelet and antifibrinolytic activity
4) Little or no weight gain
5) FDA approved combination therapy with insulin
6) Safe and effective for use in the pediatric
population
7) ↑ Levels of plasma adiponectin & ↓ TNF α
8) Stimulates GLUT4 expression
68. Why Glibenclamide is more potent and
longer acting than other SU
1. May accumulate within cells and directly stimulate
exocytosis of insulin granules
2. Greater/longer binding to SUR-1 receptors
3. Slower absorption and distribution
4. Inhibition of hepatic insulinase
5. Suppression of several counter-regulatory hormones
6. More suppression of Hepatic Glucose Output
7. May stimulate insulin synthesis
69. Adverse effects
• Hypoglycemia:
• GI disturbances: Nausea, vomiting, metallic
taste, diarrhoea & flatulence
• Weight gain
• Hypersensitivity
• Not safe in pregnancy
• Chlorpropamide:
– cholestatic jaundice, dilutional hyponatremia,
antabuse reaction
70. Contraindications
1. Allergy to SU
2. Renal failure
3. Significant hepatic dysfunction
4. Severe infections, stress, trauma, major surgery,
CVA
5. Pregnancy (except Glibenclamide)
71. Selection of SU
Clinical conditions Agents
Fasting & postprandial
hyperglycemia
Long acting/Intermediate acting Su.
Only postprandial hyperglycemia Glipizide
Renal impairment Glipizide
GDM Glibenclamide
Elderly (> 65) Avoid Glibenclamide, chlorpropamide
Alcoholics Avoid chlorpropamide
DM & IHD Avoid Glibenclamide.
DM, HT & Edema legs Avoid chlorpropamide
72. Meglitinide analogs
• Quick & short acting insulin releasers
• MOA: same as Sulfonylureas but act through
different receptor SUR2
• Mainly used to control Post prandial
hyperglycemia
• Less hypoglycemia
73. Repaglinide
• Well tolerated in elderly patients and in renal
impairment
• Adverse effects:
– Mild headache, dyspepsia, arthralgia, headache
• Indicated in type II DM
• Dose : start 0.5mg with meals can ↑ 16mg/day
74. Nateglinide
• Stimulates first phase of insulin secretion
• More rapid acting & shorter duration than
repaglinide
• Mainly used in post prandial hyperglycemia
without producing late phase hypoglycemia
• Little effect on fasting BSL
• Adverse effects: dizziness, nausea, flu like
symptoms
• Dose: 60 to 180 mg TDS with meals
75. Biguanides
• Metformin & phenformin
• Little or no hypoglycemia
• Also improves the lipid profile in type II
diabetic patients
• Metformin dose = 0.5 to 2.5 g/day in 2-3
divided doses
76. Mechanism of action
• Suppress hepatic & renal gluconeogenesis
• ↑ uptake & utilization of glucose by skeletal
muscles which reduces insulin resistance
• Inhibit alimentary absorption of glucose
• Interfere with mitochondrial respiratory chain
& promote peripheral glucose utilization by
enhancing anaerobic glycolysis
77. METFORMIN - INDICATIONS
• Obese Type 2 Diabetes.
• Secondary Sulfonylurea Failure state.
• To reduce Insulin requirements.
• Can be combined with Sulfonylureas,
Glitazones, Insulin.
78. Adverse effects
• Anorexia, nausea, vomiting, diarrhoea
• Metallic taste
• Loss of weight
• Skin rashes
• Lactic acidosis: rare
• Vitamin B12 deficiency: due to malabsorption
Usually does not cause hypoglycemia even in
large doses
80. Thiazolidinediones (Glitazones)
Rosiglitazone & pioglitazone Selective agonists of PPAR
Bind to nuclear PPAR
Activate insulin responsive genes - regulate
carbohydrate & lipid metabolism
Sensitize the peripheral tissues to insulin
↓blood glucose by
↑ Glucose transport into
muscle & adipose tissue
Inhibit hepatic
gluconeogenesis
Promote
lipogenesis
81. Thiazolidinediones
• Hyperglycemia, hyperinsulinemia, and
elevated HbA1c levels are improved.
• Pioglitazone has no effect on LDL levels, ↓
triglyceride & ↑ HDL
• Rosiglitazone has inconsistent effect on lipid
profile it ↑ HDL & LDL levels
• The TZDs lead to a favorable redistribution of
fat from visceral to subcutaneous tissues.
82. • Pioglitazone:
– 15 to 45 mg once daily orally
• Rosiglitazone:
– 4 to 8 mg once daily orally
• Pt who benefit most are type II DM with
substantial amount of insulin resistance
• Also used in PCOD
• Monotherapy – Hypoglycemia rare
• Add-on Therapy – readjust dosage.
• Takes one month to act
83. Adverse effects
• Weight gain: due to fluid retention & edema
• ↑ Extracellular fluid volume
• Worsening of CHF
• ↑ Deposition of subcutaneous fat
• Mild anemia: due to hemodilution
• Hepatotoxicity : rare
• Rosiglitazone: ↑risk of fractures especially in
elderly women
86. Acarbose
• Complex oligosaccharide
• Inhibits a-glucosidase as well as a-amylase
• Reduces postprandial hyperglycemia without
increasing insulin levels
• Regular use reduces weight
• In prediabetics reduces occurrence of type II
DM, hypertension & cardiac disease
• Dose: 50 to 100 mg TDS
• Given just before food or along with food
87. Adverse effects
• Flatulence, diarrhoea, abdominal pain
• Do not cause hypoglycemia by themselves but
may cause if used with Sulfonylureas
• If hypoglycemia occurs should not be treated
with routine sugar (sucrose),
• Glucose should be used
Contraindicated in inflammatory bowel disease
& intestinal obstruction
88. 88
Voglibose
• Advantages over Acarbose and Miglitol
– 20-30 times more potent then acarbose
– Does not affect digoxin bioavailability unlike
acarbose
– No dosage adjustment required in renal
impairment patients unlike miglitol
– Superior tolerability
– Dose: 0.2 to 5 mg
89. Newer drugs for Type II DM
• GLP-1 Analogues
– Exenatide
– Liraglutide
• DPP-IV Inhibitors
– Sitagliptin
– Vildagliptin
– Alogliptin
• Amylin analog:
Pramlintide
90. Exenatide
• Synthetic GLP I analogue resistant to DDP IV
• ↑ Post prandial insulin release
• Supresses glucagon release
• Supresses appetite and slows gastric emptying
• injected SC twice daily 1 hour before meals
acts for 6 to 10 hours
• Nausea is important side effect
91. Sitagliptin
• Orally active inhibitor of DPP-4
• Prevents degradation of endogenous GLP-I
• Dose: 100mg a day
• Mainly used in post prandial hyperglycemia
• No action on weight and lipids
• Costly
92. Pramlintide
• Synthetic amylin analog
• Improves overall glycaemic control,↓ PPG
• Reduces BW : anorectic action
• Well tolerated
• Given SC before meals
• SE: GI disturbances/Less hypoglycemia when
used alone
• Can be used in type I DM
101. Hyperglycemic Hyperosmolar Non-
Ketotic Coma (HHNC)
• can occur when the action of insulin is severely
inhibited
• seen in pts. w/t T2DM
Precipitating factors:
infection, renal failure, MI, CVA, GI hemorrhage,
pancreatitis, CHF, TPN, surgery, dialysis, steroids
S/Sx:
polyuria oliguria (renal insufficiency)
lethargy
temp, PR, BP, signs of severe fluid deficit
Confusion, seizure, coma
Blood glucose level > 600 mg/100 ml.
102. Interventions for DKA and
Hyperosmolar Coma
• Regular insulin IV push or IV drip
• 0.9% NaCl IV – 1 L during the 1st hr, 2-8 L over 24
hrs.
• administer sodium bicarbonate IV to correct acidosis
• Monitor electrolyte levels, esp. serum K+ levels
• administer K+, monitor UO hourly (30ml/hr)
103. SOMOGYI EFFECT
TOO MUCH INSULIN
HYPOGLYCEMIA
GLUCAGON IS RELEASED
LIPOLYSIS
GLUCONEOGENESIS
GLYCOGENOLYSIS
REBOUND
HYPERGLYCEMIA
+
KETOSIS
104. DAWN PHENOMENON
• The "dawn effect," also called the "dawn
phenomenon," is the term used to describe an
abnormal early-morning increase in blood
sugar (glucose) — usually between 2 a.m. and
8 a.m. in people with diabetes.
105. CHRONIC COMPLICATIONS OF
DIABETES MILLETUS
• Degenerative changes in the vascular system
– Atherosclerosis
• Neuropathy from
– Vascular insufficiency
– Hyperglycemia
• Eye complications from anoxia
– Cataract
– Diabetic retinopathy
– Retinal detachment
106.
107.
108. Interventions and foot care practices
–Cleanse and inspect the feet daily.
–Wear properly fitting shoes.
–Avoid walking barefoot.
–Trim toenails properly.
–Report nonhealing breaks in the skin.
109. Wound Care
• Wound environment
• Debridement
• Elimination of pressure on infected area
• Growth factors applied to wounds
110. SUMMARY
• Treatable, but not curable.
• Preventable in obesity, adult client.
• Controllable- DIET and EXERCISE
• Diagnostic Tests
• Signs and symptoms of hypoglycemia and
hyperglycemia.
• Treatment of hypoglycemia and hyperglycemia
– diet and oral hypoglycemics.
Monitoring, teaching and assessing for
complications.